New study identifies factors associated with incomplete chemotherapy for colon cancer

May 02, 2006

Physical frailty, treatment complications, and lack of social and psychological support may explain why elderly stage III colon cancer patients do not complete a course of chemotherapy after surgery, according to a study in the May 3 Journal of the National Cancer Institute.

Several trials in the late 1980s led a 1990 National Institutes of Health Consensus Panel to recommend adjuvant chemotherapy, or chemotherapy given after surgical removal of a tumor, for stage III colon cancer patients. However, despite recommendations, many patients do not initiate or complete adjuvant chemotherapy.

Sharon Dobie, M.D., of the University of Washington in Seattle, and colleagues analyzed data from 3,193 stage III colon cancer patients from the Surveillance, Epidemiology, and End Results (SEER) registries, who began adjuvant chemotherapy treatments. Patients, identified through Medicare claims, were assessed by whether they completed their chemotherapy treatment, as well as by their sociodemographic, clinical, and environmental characteristics and their physicians' characteristics.

The authors found that of the 3,193 patients who chose to initiate chemotherapy, 2,497 (78.2%) of patients completed a course of adjuvant chemotherapy. Patients who completed adjuvant chemotherapy had a reduced risk of death. An incomplete course of chemotherapeutic treatment was associated with factors related to physical frailty, treatment complications, and a lack of social and psychological support. Their physicians' characteristics did not affect whether they completed chemotherapy. African-Americans were equally likely to finish treatment as Caucasians.

The authors write, "From these findings, interventions to improve social and physical support throughout the treatment course could be implemented to test whether such support improves rates of chemotherapy completion in elderly colon cancer patients."

In an accompanying editorial, Victor R. Grann, M.D., from Columbia University's College of Physicians and Surgeons, and Franco M. Muggia, M.D., from New York University School of Medicine, suggest the paper's results verify the importance of completion of adjuvant chemotherapy for optimal survival. They write, "The findings are worthy of comment and should add to the education of medical oncologists and other physicians who participate in the management of patients undergoing curative resections for colon cancer."
-end-
Contacts:

Article: Claire Hagerty, Assistant Director for Media Relations, 206-685-1323, clareh@u.washington.edu
Editorial: Victor Grann, Columbia University, 212-305-9529, vrg2@columbia.edu

Citations:


Article: Dobie SA, Baldwin L-M, Dominitz JA, Matthews B, Billingsley K, Barlow W. Completion of Therapy by Medicare Patients with Stage III Colon Cancer. J Natl Cancer Inst 2006; 98:610-619.
Editorial: Grann VR, Muggia FM. Completion Rates of Adjuvant Chemotherapy for Colon Cancer: A Historical Perspective. J Natl Cancer Inst 2006; 98:570-571.

Note: The Journal of the National Cancer Institute is published by Oxford University Press and is not affiliated with the National Cancer Institute. Attribution to the Journal of the National Cancer Institute is requested in all news coverage. Visit the Journal online at http://jncicancerspectrum.oxfordjournals.org/.

Journal of the National Cancer Institute

Related Chemotherapy Articles from Brightsurf:

Chemotherapy is used to treat less than 25% of people with localized sarcoma
UCLA researchers have found that chemotherapy is not commonly used when treating adults with localized sarcoma, a rare type of cancer of the soft tissues or bone.

Starved cancer cells became more sensitive to chemotherapy
By preventing sugar uptake, researchers succeeded in increasing the cancer cells' sensitivity to chemotherapeutic treatment.

Vitamin D could help mitigate chemotherapy side effects
New findings by University of South Australia researchers reveal that Vitamin D could potentially mitigate chemotherapy-induced gastrointestinal mucositis and provide relief to cancer patients.

Less chemotherapy may have more benefit in rectal cancer
GI Cancers Symposium: Colorado study of 48 patients with locally advanced rectal cancer receiving neoadjuvant chemotherapy, found that patients receiving lower-than-recommended doses in fact saw their tumors shrink more than patients receiving the full dose.

Male fertility after chemotherapy: New questions raised
Professor Delb├Ęs, who specializes in reproductive toxicology, conducted a pilot study in collaboration with oncologists and fertility specialists from the McGill University Health Centre (MUHC) on a cohort of 13 patients, all survivors of pediatric leukemia and lymphoma.

'Combo' nanoplatforms for chemotherapy
In a paper to be published in the forthcoming issue in NANO, researchers from Harbin Institute of Technology, China have systematically discussed the recent progresses, current challenges and future perspectives of smart graphene-based nanoplatforms for synergistic tumor therapy and bio-imaging.

Nanotechnology improves chemotherapy delivery
Michigan State University scientists have invented a new way to monitor chemotherapy concentrations, which is more effective in keeping patients' treatments within the crucial therapeutic window.

Novel anti-cancer nanomedicine for efficient chemotherapy
Researchers have developed a new anti-cancer nanomedicine for targeted cancer chemotherapy.

Ending needless chemotherapy for breast cancer
A diagnostic test developed at The University of Queensland might soon determine if a breast cancer patient requires chemotherapy or would receive no benefit from this gruelling treatment.

A homing beacon for chemotherapy drugs
Killing tumor cells while sparing their normal counterparts is a central challenge of cancer chemotherapy.

Read More: Chemotherapy News and Chemotherapy Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.